Should I buy or sell Arbutus Biopharma stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ABUS shares. View ABUS analyst ratings or view top-rated stocks .

What is Arbutus Biopharma's stock price target for 2024?

3 brokerages have issued twelve-month target prices for Arbutus Biopharma's shares. Their ABUS share price targets range from $4.00 to $5.00. On average, they predict the company's stock price to reach $4.33 in the next year. This suggests a possible upside of 58.7% from the stock's current price. View analysts price targets for ABUS or view top-rated stocks among Wall Street analysts .

How have ABUS shares performed in 2024?

Arbutus Biopharma's stock was trading at $2.50 at the start of the year. Since then, ABUS shares have increased by 9.2% and is now trading at $2.73. View the best growth stocks for 2024 here .

Are investors shorting Arbutus Biopharma?

Arbutus Biopharma saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 4,550,000 shares, an increase of 10.2% from the March 15th total of 4,130,000 shares. Based on an average daily trading volume, of 1,320,000 shares, the short-interest ratio is currently 3.4 days. View Arbutus Biopharma's Short Interest .

When is Arbutus Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ABUS earnings forecast .

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Co. (NASDAQ:ABUS) posted its quarterly earnings data on Thursday, February, 29th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). The biopharmaceutical company had revenue of $2.15 million for the quarter, compared to the consensus estimate of $4.74 million. Arbutus Biopharma had a negative trailing twelve-month return on equity of 57.82% and a negative net margin of 401.57%. During the same quarter in the prior year, the business earned ($0.14) EPS.

What ETFs hold Arbutus Biopharma's stock?

ETFs with the largest weight of Arbutus Biopharma (NASDAQ:ABUS) stock in their portfolio include Morningstar US Small Growth (MSGR) , iShares Genomics Immunology and Healthcare ETF (IDNA) and Amplify Treatments, Testing and Advancements ETF (GERM) . Invesco Nasdaq Future Gen 200 ETF (QQQS) .

What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO?

6 employees have rated Arbutus Biopharma Chief Executive Officer Mark J. Murray on Glassdoor.com . Mark J. Murray has an approval rating of 22% among the company's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arbutus Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP) , Chiasma (CHMA) , Bausch Health Companies (BHC) , Heat Biologics (HTBX) , Sorrento Therapeutics (SRNE) , GW Pharmaceuticals (GWPH) , Inovio Pharmaceuticals (INO) , Alibaba Group (BABA) , TherapeuticsMD (TXMD) and Novavax (NVAX) .

How do I buy shares of Arbutus Biopharma?

Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ABUS

Arbutus Biopharma (ABUS) Stock Price, News & Analysis

→ I’m officially sounding the alarm. (From Altimetry) (Ad)

Free ABUS Stock Alerts

$2.72

-0.01 (-0.37%)

(As of 09:47 AM ET)

Compare

Today's Range: $2.69
▼
$2.72
50-Day Range: $2.49
▼
$3.12
52-Week Range: $1.69
▼
$3.29

Volume: 52,418 shs
Average Volume: 1.28 million shs
Market Capitalization: $488.21 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.33

Get Arbutus Biopharma alerts:

Arbutus Biopharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 58.7% Upside
$4.33 Price Target
Short Interest: Healthy
2.53% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.97
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.39) to ($0.43) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.83 out of 5 stars

Medical Sector

560th out of 918 stocks

Pharmaceutical Preparations Industry

257th out of 427 stocks

3.5

Analyst's Opinion

Consensus Rating
Arbutus Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Arbutus Biopharma has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.53% of the outstanding shares of Arbutus Biopharma have been sold short.
Short Interest Ratio / Days to Cover
Arbutus Biopharma has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Arbutus Biopharma has recently increased by 10.17%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Arbutus Biopharma does not currently pay a dividend.
Dividend Growth
Arbutus Biopharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ABUS.

3.3

News and Social Media Coverage

News Sentiment
Arbutus Biopharma has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Arbutus Biopharma this week, compared to 2 articles on an average week.
Search Interest
7 people have searched for ABUS on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.
MarketBeat Follows
5 people have added Arbutus Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Arbutus Biopharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.40% of the stock of Arbutus Biopharma is held by insiders.
Percentage Held by Institutions
43.79% of the stock of Arbutus Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Arbutus Biopharma are expected to decrease in the coming year, from ($0.39) to ($0.43) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Arbutus Biopharma is -6.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Arbutus Biopharma is -6.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Arbutus Biopharma has a P/B Ratio of 4.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Arbutus Biopharma Stock (NASDAQ:ABUS)

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

ABUS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ABUS Stock News Headlines

April 18, 2024 | globenewswire.com

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

April 16, 2024 | americanbankingnews.com

Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Up 10.2% in March

April 19, 2024 | Altimetry (Ad)

I’m officially sounding the alarm.

AI has been the hottest financial story of 2023. And rightly so – AI stocks have beat the broader market by over 62%. But right now, my system is warning me that many AI stocks are riding higher on hype alone.

April 10, 2024 | seekingalpha.com

Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains

April 4, 2024 | msn.com

Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge

April 4, 2024 | markets.businessinsider.com

Arbutus Biopharma Reports Claim Construction Ruling In Patent Infringement Lawsuit Against Moderna

April 4, 2024 | globenewswire.com

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

April 3, 2024 | seekingalpha.com

Arbutus Biopharma jumps after claim construction order in patent fight with Moderna

April 19, 2024 | Altimetry (Ad)

I’m officially sounding the alarm.

April 1, 2024 | finance.yahoo.com

Is Arbutus Biopharma (NASDAQ:ABUS) In A Good Position To Deliver On Growth Plans?

March 19, 2024 | finance.yahoo.com

ABUS Jan 2025 7.000 call

March 12, 2024 | msn.com

Arbutus Biopharma to Participate in Prominent Investor Conferences

March 8, 2024 | globenewswire.com

Arbutus to Participate in Two Upcoming Investor Conferences

March 3, 2024 | finance.yahoo.com

Arbutus Biopharma Corporation (NASDAQ:ABUS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

March 2, 2024 | finance.yahoo.com

Analysts Just Made A Major Revision To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenue Forecasts

March 1, 2024 | finance.yahoo.com

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call Transcript

March 1, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Arbutus Biopharma on Strong Clinical Outlook and Litigation Prospects

March 1, 2024 | finance.yahoo.com

Q4 2023 Arbutus Biopharma Corp Earnings Call

February 29, 2024 | finanznachrichten.de

Arbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

February 29, 2024 | finance.yahoo.com

Arbutus Biopharma Corp (ABUS) Reports Year-End Financial Results and Progress in Clinical Trials

February 29, 2024 | globenewswire.com

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

February 28, 2024 | finance.yahoo.com

ABUS Jun 2024 3.000 put

February 27, 2024 | finance.yahoo.com

ABUS Apr 2024 6.000 call

February 23, 2024 | finance.yahoo.com

ABUS Apr 2024 3.000 call

February 23, 2024 | finance.yahoo.com

ABUS Sep 2024 3.000 call

February 17, 2024 | msn.com

Arbutus Biopharma Set to Announce 2023 Year-End Financial Results, Offering Insight into Hepatitis B Cure Progress

February 15, 2024 | finance.yahoo.com

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

See More Headlines

Receive ABUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ABUS
CUSIP: N/A
CIK: 1447028
Web: www.arbutusbio.com
Phone: (267) 469-0914
Fax: 604-419-3201
Employees: 73
Year Founded: 1992

Price Target and Rating

Average Stock Price Target: $4.33
High Stock Price Target: $5.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +58.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.44)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-72,850,000.00
Net Margins: -401.57%
Pretax Margin: -401.57%
Return on Equity: -57.82%
Return on Assets: -43.42%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.87
Quick Ratio: 5.87

Sales & Book Value

Annual Sales: $18.14 million
Price / Sales: 27.01
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.63 per share
Price / Book: 4.33

Miscellaneous

Outstanding Shares: 179,490,000
Free Float: 169,799,000
Market Cap: $490.01 million
Optionable: Optionable
Beta: 2.03

Social Links

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Michael J. McElhaugh (Age 49)
Co-Founder, Interim President, CEO & Director
Comp: $606.62k
Dr. Michael J. Sofia Ph.D. (Age 66)
Chief Scientific Officer
Comp: $628.43k
Mr. David C. Hastings CPA (Age 63)
CFO & Chief Accounting Officer
Comp: $647.1k
Ms. Lisa M. Caperelli
Vice President of Investor Relations
Mr. J. Christopher Naftzger BA (Age 57)
Esq., J.D., General Counsel, Chief Compliance Officer & Secretary
Ms. Shannon Briscoe SPHR
Vice President of Human Resources
Dr. Karen Sims M.D. (Age 53)
Ph.D., Chief Medical Officer
Mr. R. Hector Mackay-Dunn B.A. (Age 73)
J.D., L.L.B., Q.C., Corporate Secretary

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ABUS Stock Analysis - Frequently Asked Questions

Should I buy or sell Arbutus Biopharma stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ABUS shares.
View ABUS analyst ratings or view top-rated stocks.
What is Arbutus Biopharma's stock price target for 2024?: 3 brokerages have issued twelve-month target prices for Arbutus Biopharma's shares. Their ABUS share price targets range from $4.00 to $5.00. On average, they predict the company's stock price to reach $4.33 in the next year. This suggests a possible upside of 58.7% from the stock's current price.
View analysts price targets for ABUS or view top-rated stocks among Wall Street analysts.
How have ABUS shares performed in 2024?: Arbutus Biopharma's stock was trading at $2.50 at the start of the year. Since then, ABUS shares have increased by 9.2% and is now trading at $2.73.
View the best growth stocks for 2024 here.
Are investors shorting Arbutus Biopharma?: Arbutus Biopharma saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 4,550,000 shares, an increase of 10.2% from the March 15th total of 4,130,000 shares. Based on an average daily trading volume, of 1,320,000 shares, the short-interest ratio is currently 3.4 days.
View Arbutus Biopharma's Short Interest.
When is Arbutus Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ABUS earnings forecast.
How were Arbutus Biopharma's earnings last quarter?: Arbutus Biopharma Co. (NASDAQ:ABUS) posted its quarterly earnings data on Thursday, February, 29th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). The biopharmaceutical company had revenue of $2.15 million for the quarter, compared to the consensus estimate of $4.74 million. Arbutus Biopharma had a negative trailing twelve-month return on equity of 57.82% and a negative net margin of 401.57%. During the same quarter in the prior year, the business earned ($0.14) EPS.

What ETFs hold Arbutus Biopharma's stock?: ETFs with the largest weight of Arbutus Biopharma (NASDAQ:ABUS) stock in their portfolio include Morningstar US Small Growth (MSGR), iShares Genomics Immunology and Healthcare ETF (IDNA) and Amplify Treatments, Testing and Advancements ETF (GERM).Invesco Nasdaq Future Gen 200 ETF (QQQS).
What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO?: 6 employees have rated Arbutus Biopharma Chief Executive Officer Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among the company's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Arbutus Biopharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX).
How do I buy shares of Arbutus Biopharma?: Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ABUS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial